{"url_path":"/sec/pmvp/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1699382/0001193125-26-218227-index.html","accession_number":"0001193125-26-218227","cik":"0001699382","ticker":"PMVP","issuer_name":"PMV Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1699382/0001193125-26-218227-index.html","primary_entity_key":"0001699382","primary_entity_name":"PMV Pharmaceuticals, Inc."},"word_count":100,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.\n\n(a) Unregistered Sales of Equity Securities\n\nNone.\n\n(b) Use of Proceeds\n\nOur initial public offering of our common stock was effected pursuant to a registration statement on Form S-1 (File No. 333-248627), which was declared effective by the SEC on September 24, 2020. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on September 24, 2020.\n\n(c) Issuer Purchases of Equity Securities.\n\nNone."}